Compound, data | Intravenous: AUC | Oral | ||
---|---|---|---|---|
AUC | Cmax | tmax | ||
ng × hr/ml | ng × hr/ml | ng/ml | hr | |
Pravastatin | ||||
Observed | 171.2 | 86.5–111 | 27.9–49.5 | 1.2–1.7 |
Base model | 176.1 (0.97) | 199 (0.43–0.56) | 67.9 (0.41–0.73) | 0.97 |
HEK293 plasma | 147.1 (1.16) | 95.9 (0.90–1.16) | 33.4 (0.84–1.48) | 0.93 |
HEK293 buffer | 157.8 (1.08) | 133 (0.65–0.83) | 46.1 (0.61–1.07) | 0.94 |
Rosuvastatin | ||||
Observed | 164 | 253–410 | 30.1–53.5 | 3.0–5.0 |
Base model | 157.5 (1.04) | 197 (1.28–2.08) | 17.4 (1.73–3.07) | 3.10 |
HEK293 plasma | 197.8 (0.83) | 412 (0.61–1.00) | 36.3 (0.83–1.47) | 3.23 |
HEK293 buffer | 205.7 (0.80) | 454 (0.56–0.90) | 40.0 (0.75–1.34) | 3.26 |
Repaglinide | ||||
Observed | 61.4 | 27.2–69.0 | 20.2–47.9 | 0.50–0.90 |
Base model | 86.2 (0.71) | 36.9 (0.74–1.87) | 26.5 (0.76–1.81) | 0.57 |
HEK293 plasma | 61.7 (1.00) | 16.3 (1.67–4.23) | 14.2 (1.42–3.37) | 0.48 |
HEK293 buffer | 113.6 (0.54) | 61.7 (0.44–1.12) | 38.4 (0.53–1.25) | 0.60 |
Pitavastatin | ||||
Observed | 76.1 | 33.6 | 18.6 | 0.75 |
Base model | 87.6 (0.87) | 33.8 (0.99) | 18.3 (1.02) | 0.79 |
HEK293 plasma | 55.4 (1.37) | 10.4 (3.23) | 6.54 (2.84) | 0.69 |
HEK293 buffer | 334 (0.23) | 221 (0.15) | 62.0 (0.30) | 1.09 |
The ratio (observed/predicted) is in parentheses. tmax, time to maximal concentration.